Supplementary Data from First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Authors:
- Richard D. KimRKRichard D. Kim
- Debashis SarkerDSDebashis Sarker
- Tim MeyerTMTim Meyer
- Thomas YauTYThomas Yau
- Teresa MacarullaTMTeresa Macarulla
- Joong-Won ParkJPJoong-Won Park
- Su Pin ChooSCSu Pin Choo
- Antoine HollebecqueAHAntoine Hollebecque
- Max W. SungMSMax W. Sung
- Ho-Yeong LimHLHo-Yeong Lim
- Vincenzo MazzaferroVMVincenzo Mazzaferro
- Joerg TrojanJTJoerg Trojan
Open Access
- 3 April 2023
- other
- Published by American Association for Cancer Research (AACR)